Tositumomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tositumomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD20
Clinical data
Trade names Bexxar
AHFS/Drugs.com monograph
MedlinePlus a609013
Legal status ?
Identifiers
CAS number 192391-48-3 YesY
ATC code V10XA53 (sequential regimen with 131I form)
DrugBank DB00081
UNII 0343IGH41U YesY
KEGG D08622 YesY
ChEMBL CHEMBL1201604 N
Chemical data
Formula C6416H9874N1688O1987S44 
Mol. mass 143859.7 g/mol
 N (what is this?)  (verify)

Tositumomab is a drug for the treatment of follicular lymphoma. It is an IgG2a anti-CD20 monoclonal antibody derived from immortalized mouse cells.

Tositumomab is applied in a sequential infusion followed by iodine (131I) tositumomab, which is the same antibody covalently bound to the radionuclide iodine-131 (131I).[1] 131I emits both beta and gamma radiation and decays with a half-life of 8 days.

Clinical trials have established the efficacy of the tositumomab/iodine (131I) tositumomab regimen in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.

This drug combination is manufactured by Corixa (now GlaxoSmithKline). It sells in the U.S. under the trade name Bexxar. Sale of the drug will be discontinued in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2]

Bexxar was developed by Mark Kaminski and Richard Wahl.[citation needed][clarification needed]

There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.[3]

References[edit]

External links[edit]

  • Bexxar regimen entry in the public domain NCI Dictionary of Cancer Terms